The EU opened a formal investigation into Amazon on Wednesday centered on how the e-commerce giant uses merchants' data.Technologyread more
Investors are keen to find out how looming interest rate cuts will impact the second biggest U.S. lender by assets.Financeread more
IAC is set to invest $250 million in Turo, a peer-to-peer car-sharing firm that is often referred to as the "Airbnb for cars."Technologyread more
Mortgage interest rates surged last week to their highest level in a month, and consequently homebuyers turned on their heels.Real Estateread more
One semiconductor stock has soared above the rest since spring, and one of its biggest cheerleaders sees a larger breakout ahead.Trading Nationread more
U.S. officials see the deal as a threat to NATO, for which Turkey provides the second-largest military.World Politicsread more
Google's services have been blocked in China for several years, but the company still has a business there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
China may have signaled it's going more hard-line on trade, but it could be a good thing, former U.S. negotiator Clete Willems told CNBC.World Economyread more
Support for U.S. President Donald Trump increased slightly among Republicans after he lashed out on Twitter over the weekend in a racially charged attack on four minority...Politicsread more
A key read on the industry, the Architecture Billings Index, fell into negative territory in June, according to the American Institute for Architects. Inquiries for new...Real Estateread more
While the vote served as a show of solidarity for Democrats, it recommended no substantive penalty against Trump.Politicsread more
John Maraganore, CEO of biotech Alnylam Pharmaceuticals, said Wednesday his industry focuses on innovation, not pushing prices on decades-old drugs higher to make a profit.
Maraganore was responding to outrage over how Turing Pharmaceuticals, a start-up run by a former hedge fund manager, had jacked up the price of Daraprim, approved by the FDA in 1953, by more than 5,000 percent overnight.
In an interview Monday on CNBC, Turing CEO Martin Shkreli said the drug had been priced too low and his company needed to generate profits to spend on new research and development.
A day later, Shkreli said he would lower the cost of the drug used to fight toxoplasmosis, a parasite infection that can cause serious problems for people with weakened immune systems as a result of AIDS, chemotherapy, or pregnancy. He told NBC News the price, which had been raised to $750 a pill, would return to $13.50 in a few weeks.
"This is not what we do in the biotech industry," Alnylam's Maraganore told CNBC's "Squawk Box " on Wednesday. "We're about innovation, patience and 21st century medicines. We're not about repricing drugs from the 1950s to make a profit. It's not how we focus our R&D investments."
"Most Americans get it when people work hard, they take risks and then they get rewarded. But people do tend to hate it and dislike it when people try to cheat the system," he said.
The outrage sparked by Turing, which bought Daraprim from Impax Laboratories in August for $55 million, also drew the attention of Democratic presidential candidate Hillary Clinton, whose tweet on the issue Monday knocked biotech stocks sharply lower.
Clinton on Tuesday outlined a plan that she said would limit how much patients have to pay out of pocket for medications each month.
Maraganore said prices for new drugs are not too high. "The focus should be on value and access. There's a lot of data that shows that drugs actually reduce overall costs," he contended—claiming money spent on medications can lower health-care expenditures.
—NBC News and Reuters contributed to this report.